Tirzepatide
A synthetic 39-amino acid peptide designed to co-activate both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Studied for metabolic regulation, appetite suppression, and body composition modulation in preclinical and clinical research settings.
01 Mechanism of Action
Tirzepatide is a synthetic peptide that functions as a dual co-agonist at both GIP and GLP-1 receptors — two incretin hormone receptors expressed in the gut, pancreas, adipose tissue, and central nervous system. This dual-receptor activity distinguishes tirzepatide from single-target GLP-1 agonists such as semaglutide.
Upon receptor binding, tirzepatide activates intracellular cAMP-dependent signaling cascades that result in enhanced insulin secretion (glucose-dependent), suppressed glucagon release, delayed gastric emptying, and satiety signaling via hypothalamic pathways. GIP receptor activation additionally modulates lipid metabolism and adipogenesis at the adipocyte level — an effect absent in GLP-1-only agonists.
The molecule contains a C20 fatty diacid modification at lysine-26, enabling reversible albumin binding that extends plasma half-life to approximately five days, supporting once-weekly dosing intervals in clinical protocols.
02 Clinical Efficacy Data
The SURMOUNT-1 phase 3 trial (NCT04184622) enrolled 2,539 adults with obesity and evaluated tirzepatide at three dose levels over a 72-week treatment period. The primary endpoint was percentage change in body weight from baseline.
| Dose | Mean % Body Weight Change | Mean Absolute Loss | Responders ≥20% Loss |
|---|---|---|---|
| 5 mg / week | −16.0% | ~35.5 lbs (16.1 kg) | 30% |
| 10 mg / week | −21.4% | ~48.9 lbs (22.2 kg) | 50% |
| 15 mg / week | −22.5% | ~52.0 lbs (23.6 kg) | 57% |
| Placebo | −2.4% | ~5.3 lbs (2.4 kg) | 3% |
Source: SURMOUNT-1 (NCT04184622) — Jastreboff et al., NEJM 2022. Data presented for reference purposes.
Tirzepatide vs. Semaglutide — SURMOUNT-5
The SURMOUNT-5 trial (NCT05822830) conducted the first direct comparison between tirzepatide and semaglutide (2.4 mg weekly) for weight management over 72 weeks. Participants were escalated to maximum tolerated doses of each compound.
Source: SURMOUNT-5 (NCT05822830) — Lincoff et al., NEJM 2025.
03 Observed Research Effects
The following effects have been documented across tirzepatide clinical trials. This information is presented for research reference only and does not constitute medical guidance.
Common Reported Effects (≥5% Incidence)
Gastrointestinal effects predominate during dose escalation and typically diminish after four to eight weeks at stable doses. Gradual titration protocols reduce GI adverse event burden in clinical settings.
Clinically Significant Signals Warranting Monitoring
- Acute pancreatitis — Severe, persistent abdominal pain radiating to the back has been reported. Causal relationship not definitively established; pancreatitis history is a clinical consideration.
- Gallbladder pathology — Cholelithiasis and cholecystitis observed at elevated rates in trials, consistent with rapid weight loss rather than direct drug effect.
- Hypoglycemia risk — Elevated when co-administered with insulin secretagogues. Glucose-dependent mechanism reduces but does not eliminate risk.
- Thyroid C-cell proliferation — Observed in rodent models at all doses; human relevance uncertain. Contraindicated in subjects with personal/family history of medullary thyroid carcinoma in clinical settings.
- Renal function changes — Dehydration secondary to GI effects can impair renal clearance; fluid balance monitoring is indicated in sensitive populations.
- Retinal complications — Rapid glycemic improvement in T2D subjects associated with diabetic retinopathy worsening; baseline ophthalmologic assessment recommended in diabetic research populations.
04 Chemical & Physical Profile
05 Reconstitution Reference
The following concentrations are commonly used in published tirzepatide preclinical research protocols. All calculations assume a 5 mg lyophilized vial.
| Bacteriostatic Water Added | Resulting Concentration | Volume per 100 µg dose | Doses per Vial |
|---|---|---|---|
| 1.0 mL | 5,000 µg/mL (5 mg/mL) | 0.02 mL (20 µL) | 50 |
| 2.0 mL | 2,500 µg/mL (2.5 mg/mL) | 0.04 mL (40 µL) | 50 |
| 5.0 mL | 1,000 µg/mL (1.0 mg/mL) | 0.10 mL (100 µL) | 50 |
06 Research Literature
The following publications form the primary evidence base for tirzepatide's pharmacology and clinical profile. All are publicly accessible via the referenced journals.
Order Tirzepatide · 5 mg Vial
≥98.5% HPLC purity · CoA from Freedom Diagnostics · Cold shipped · Lot 2603